Eli Lilly filed six federal lawsuits on August 12, 2026 against US companies it accuses of selling black-market versions of retatrutide, the triple agonist it still has in Phase 3 trials. Four of the six cases were filed in Texas. The named defendants are a mix of peptide sellers, a compounding pharmacy and a medical spa — and the shape of that list is the story, because it is the first time Lilly has taken the research-supply channel to court by name rather than referring it to regulators.
Alongside the filings, Lilly published an open call to online platforms, credit card companies, payment processors and shipping carriers to cut off the sellers' infrastructure. For anyone who follows peptide supply, that second half is the more consequential document. Litigation moves in years; a processor decision moves in a week.
Research-context information only. This article reports on newly filed civil complaints and a company press release as published. A complaint is an allegation, not a finding, and none of these cases has been decided. Nothing here is medical or legal advice. Retatrutide is an investigational molecule in Phase 3 clinical trials and is not approved for any use in humans in any country; research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity or potency as sold. Consult a licensed physician for personal medical decisions.
The six cases
Lilly filed each suit separately rather than as a single consolidated action, which spreads them across four federal districts:
| Case | Court |
|---|---|
| Eli Lilly & Co. v. Aesthetic Envy Cosmetic Centers LLC | N.D. Cal. |
| Eli Lilly & Co. v. Astra LLC | W.D. Tex. |
| Eli Lilly & Co. v. Legendary Peptides, LLC | E.D. Tex. |
| Eli Lilly & Co. v. Striker Pharmacy, LLC | S.D. Tex. |
| Eli Lilly & Co. v. Texas Peptides Inc. | W.D. Tex. |
| Eli Lilly & Co. v. Lone Star Peptide Co. | S.D. Tex. |
Lilly's stated theory across the group is that the defendants marketed retatrutide products to consumers for weight loss while the molecule remains investigational, and that some of them labelled the material "research use only" while intending and understanding it to be used by humans. The company also says product in this channel is frequently sourced from unregulated foreign manufacturers. David A. Hyman, M.D., Lilly's chief medical officer, put the company's position in one line: "What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk."
Those are Lilly's characterisations, made in complaints it has an obvious commercial interest in bringing. No defendant has answered yet, and none of the six had announced a closure as of publication.
The filings are the visible tip of a much larger private enforcement operation. Lilly says it has reported more than 14,000 websites, advertisements, social media posts and product listings marketing retatrutide across more than 100 countries to internet service providers, social platforms and e-commerce companies, and has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards. Six lawsuits against a 14,000-listing problem is not an attempt at coverage. It is an attempt at precedent.
The ask that actually moves supply
The lawsuits will take years. The press release will not.
In the same announcement, Lilly asked four groups to act without waiting for a court: regulators and law enforcement to prioritise cross-border enforcement, social media and e-commerce platforms to proactively block listings, credit card companies, payment processors and shipping carriers to cut off transaction infrastructure, and healthcare providers to raise awareness with patients.
The third of those is the one to watch. On our own tracking of the past two years, payment processing has been the most reliable predictor of whether a peptide vendor stays in business — not FDA letters, not litigation, not state pharmacy rules. Vendors that lost a processor disappeared within weeks; vendors that kept one absorbed regulatory pressure and continued trading. Our record of which vendors shut down across 2025 and 2026 is, read closely, mostly a record of banking relationships ending. The same dynamic surfaced in the compounding world's own litigation: Strive's antitrust complaint against Lilly and Novo Nordisk alleged processor interference as one of three chokepoints, and that case was dismissed on August 3 without the processor theory ever being tested.
What that means practically is that the near-term signal is not a docket entry. It is checkout friction — cards declining, a vendor switching processors, crypto or ACH appearing as the only option, or shipping delays on inbound stock. Those changes show up in weeks, and they show up per-vendor rather than across the market at once.
What changes for buyers, and what does not
Three things are worth separating, because reporting on this story has run them together.
The suits are against six named entities, not the channel. None of the six defendants is a vendor we list or track. Nothing in the filings names, binds or restrains any other seller, and no court has ordered anything yet. Our comparison surfaces are unchanged by the litigation itself, and current per-milligram pricing, coupon status and COA availability are live on the retatrutide buying surface.
Retatrutide's legal status did not change on August 12 — it was already investigational. The compound has no approval anywhere in the world. Reporting on the cases notes the FDA's existing position that sales of unapproved retatrutide to consumers are unlawful and that the molecule cannot lawfully be compounded, which is why the PCAC 503A peptide vote in late July covered BPC-157, KPV, TB-500, MOTS-c, epitalon and semax and no GLP-1-class compound. Our legality guide sets out the research-use-only distinction in full.
Concentration of risk is the real variable. A market served by six large sellers is fragile in a way that a market served by thirty is not. What this campaign is designed to do — flag listings, pressure processors, refer entities to licensing boards — raises the operating cost of every seller at once, and the vendors with the thinnest margins and the most improvised payment arrangements feel it first. For a buyer, that argues for tracking who currently holds stock, price and a published COA rather than assuming last quarter's answer still holds.
